相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer
Zijian Chen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
DNA methylation-based signature of CD8+tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer
Qi Zou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR plus NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Hui Xia et al.
CLINICAL LUNG CANCER (2020)
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays
Nicole Pfarr et al.
GENES CHROMOSOMES & CANCER (2020)
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
US Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2020)
Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
Yun Guo et al.
ONCOLOGIST (2020)
Molecular characterization of cancers with NTRK gene fusions
Zoran Gatalica et al.
MODERN PATHOLOGY (2019)
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
Dennis P. O'Malley et al.
MODERN PATHOLOGY (2019)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C. Marchio et al.
ANNALS OF ONCOLOGY (2019)
Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
E. M. O'Reilly et al.
ANNALS OF ONCOLOGY (2019)
Larotrectinib for the treatment of TRK fusion solid tumors
Theodore W. Laetsch et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
457PDKinase fusions in colorectal cancers: A unique biologic subset
R Madison et al.
ANNALS OF ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution
Aaron M. Newman et al.
BIOINFORMATICS (2014)
Trimmomatic: a flexible trimmer for Illumina sequence data
Anthony M. Bolger et al.
BIOINFORMATICS (2014)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
分享论文
